Wharton's Jelly derived mesenchymal stem cell therapy (NextCell)

N/A

Report date: 2025/03/07 11:49:12

Base Information

Drug NameWharton's Jelly derived mesenchymal stem cell therapy (NextCell)
Drug Alias NameWharton's Jelly骨髓间充质干细胞疗法Umbilical cord derived stem cellsProTrans
ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Diabetes Mellitus, Type 1 +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaSweden
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDiamyd Medical AbNextcell PharmaCellaviva
China Registration ClassN/A

Develop Information

Active CompaniesNextcell Pharma Ab
Inactive CompaniesResearch Institute Of The Mcgill University Health CentreMcgill University Health Centre
Active IndicationsInfluenza A virus infectionsDiabetes Mellitus, Type 1Respiratory Distress Syndrome, Adult +[4] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A